BeiGene (China) Today
| 688235 Stock | 220.88 1.11 0.51% |
PerformanceGood
| Odds Of DistressBelow Average
|
BeiGene is trading at 220.88 as of the 26th of February 2025, a 0.51% up since the beginning of the trading day. The stock's open price was 219.77. BeiGene has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 1st of June 2024 and ending today, the 26th of February 2025. Click here to learn more.
Moving together with BeiGene Stock
Moving against BeiGene Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BeiGene Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BeiGene's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BeiGene or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CoChairman CoFounder | Xiaodong Wang |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
BeiGene (688235) is traded on Shanghai Stock Exchange in China and employs 10,600 people. BeiGene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 209.82 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeiGene's market, we take the total number of its shares issued and multiply it by BeiGene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BeiGene operates under Biotechnology sector and is part of Health Care industry. The entity has 115.06 M outstanding shares.
BeiGene generates negative cash flow from operations
Check BeiGene Probability Of Bankruptcy
Ownership AllocationBeiGene holds a total of 115.06 Million outstanding shares. 30% of BeiGene outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BeiGene Ownership Details
BeiGene Risk Profiles
Although BeiGene's alpha and beta are two of the key measurements used to evaluate BeiGene's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.62 | |||
| Semi Deviation | 1.23 | |||
| Standard Deviation | 2.31 | |||
| Variance | 5.34 |
BeiGene Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BeiGene without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
BeiGene Corporate Management
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chan Lee | General VP | Profile | |
| Titus Ball | VP Officer | Profile | |
| Liza Heapes | Head Relations | Profile | |
| Wang Lai | Global RD | Profile | |
| Julia Wang | Executive Officer | Profile |
Other Information on Investing in BeiGene Stock
BeiGene financial ratios help investors to determine whether BeiGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BeiGene with respect to the benefits of owning BeiGene security.